Frequency Therapeutics secures $42m from Taiwania Capital, Axil, others

Photo: Pixabay

US-based Frequency Therapeutics, a clinical-stage biotechnology company creating small molecule drugs, has completed raising $42 million in its Series B funding round led by Taiwania Capital Management and Axil Capital.

Continue reading this story with a subscription to DealStreetAsia.

Subscribe

Contact us for corporate subscriptions at subs@dealstreetasia.com.